Figure 5.

Inhibition of cell proliferation by pertuzumab and patritumab with or without trastuzumab in heregulin‐expressing cells based on clonogenic assays. A and B, SKBR3‐HRG (A) and BT474‐HRG (B) cells were seeded in 6‐well plates and then treated with or without trastuzumab (50 μg/mL), pertuzumab (50 μg/mL), or patritumab (50 μg/mL) for 14 or 17 days. Cells were then fixed and stained with crystal violet. Representative images of clonogenic assays are shown. Total areas of colonies were quantified by ImageJ. Data represent the mean ±standard error of three independent experiments. *P < 0.05 (unpaired t test).